Diagnostic Hybrids announces FDA 510k clearance of its D3 FastPoint™ L-DFA™ Influenza A/ Influenza B Virus Identification Kit, which allows for the identification of influenza A virus and influenza B virus from a patient’s specimen in under 30 minutes. The D3 FastPoint L-DFA Influenza A/Influenza B Virus ID Kit represents the second product in the company’s D3 FastPoint L-DFA product line.
D3 FastPoint incorporates the same proprietary and proven monoclonal antibodies present in Diagnostic Hybrids’ other respiratory virus products. The kit uses the fluorescent labeling technologies of the company’s D3 UltraTM and D3 DuetTM product lines in combination with newly developed L-DFA processing technology to create a unique rapid testing format.
The new patent-pending L-DFA technology also allows for the simultaneous identification of two respiratory viruses in a single slide well. The D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit will allow laboratories to identify influenza A virus and influenza B virus infections in the same timeframe as currently available point-of-care rapid antigen tests.
“The D3 FastPoint Flu A/B kit allows laboratories to report DFA quality results within the critical care window, while confirming the specimen adequacy to avoid false negatives due to poor specimen collection, which is not possible when using rapid antigen tests” said Brooke McCutchan, MT (ASCP), Assistant Director of the Rapid Diagnostic Testing Systems Program at Diagnostic Hybrids.
“This next product in the D3 FastPoint line is the logical progression for advancing our premier L-DFA products towards a more useful alternative to rapid antigen cartridge tests,” said David R. Scholl, PhD, president and CEO of Diagnostic Hybrids. “With the D3 FastPoint Flu A/B kit, we are able to provide improved rapid respiratory testing solutions to laboratories focused on influenza A virus and influenza B virus diagnosis,” Scholl added.
Source: Diagnostic Hybrids
